Treatment of urinary tract infections with sulphonamide and/or trimethoprim. A preliminary report from a multipractice study.
In a double-blind study 1194 patients with bacteriologically diagnosed urinary tract infection were randomly selected for treatment with either 1 g sulphamethizole twice daily, 200 mg trimethoprim twice daily, or 410 mg sulphadiazine plus 90 mg trimethoprim twice daily. All drugs were administered perorally for seven days. Two weeks after commencement of therapy 70% of the patients treated with sulphamethizole, 80% of those treated with trimethoprim and 85% of those treated with sulphadiazine/trimethoprim had sterile urine. After ten weeks 25% of the patients had bacteriuria irrespective of the form of treatment. Side-effects such as skin reactions occurred in 4.1% of the patients treated with trimethoprim alone, in 1.4% of those treated with sulphamethizole and in 3.2% of those treated with trimethoprim/sulphadiazine.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013411:Sulfadiazine / Q000009:adverse effects / Q000627:therapeutic use; D013419:Sulfamethizole / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D013449:Sulfonamides; D013411:Sulfadiazine; D013419:Sulfamethizole; D014295:Trimethoprim